These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21456017)

  • 1. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
    Lipton A; Leitzel K; Ali SM; Carney W; Platek G; Steplewski K; Westlund R; Gagnon R; Martin AM; Maltzman J
    Cancer; 2011 Nov; 117(21):5013-20. PubMed ID: 21456017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
    Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
    Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
    Amir E; Ocaña A; Seruga B; Freedman O; Clemons M
    Cancer Treat Rev; 2010 Aug; 36(5):410-5. PubMed ID: 20100635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Sotelo MJ; García-Sáenz JA; Manso L; Moreno F; Ciruelos E; Callata HR; Mendiola C; Cabezas S; Ghanem I; Díaz-Rubio E
    J Cancer Res Ther; 2014; 10(4):967-72. PubMed ID: 25579538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
    Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
    J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.